ライフサイエンスコーパス: treatment duration

1 evaluate the possibility of further reducing treatment duration.

2 12 months after randomization, regardless of treatment duration.

3 ool can support clinical decision making for treatment duration.

4 containing lower presatovir dose and shorter treatment duration.

5 ampicin (35 mg/kg) will significantly reduce treatment duration.

6 rapies which have the potential to reduce TB treatment duration.

7 lation is critical to predicting clinical TB treatment duration.

8 bility of donor organ availability may limit treatment duration.

9 s collected for all patients irrespective of treatment duration.

10 lso inhibited HCMV, an effect augmented with treatment duration.

11 e documented in all patients irrespective of treatment duration.

12 ent characteristics were not associated with treatment duration.

13 as failed, and the feasibility of shortening treatment duration.

14 ch became increasingly favorable with longer treatment duration.

15 of high use of novel treatments and extended treatment duration.

16 osbuvir and ledipasvir would allow a shorter treatment duration.

17 (HIV-1) depends on both viral load (VL) and treatment duration.

18 lerability profile of SOF and by the shorter treatment duration.

19 on location, gender, age, treatment type, or treatment duration.

20 virological response (SVR) rates and shorten treatment duration.

21 bias associated with nonrandom assignment of treatment duration.

22 urce use was measured during the combination treatment duration.

23 ere not influenced by combination therapy or treatment duration.

24 n phase patients demonstrated greater median treatment duration.

25 e response, reduce tissue damage and shorten treatment duration.

26 comes appear to be no worse with the shorter treatment duration.

27 om increased cumulative dose rather than the treatment duration.

28 ensitive to BSC survival rate, and sorafenib treatment duration.

29 QD achieved SVR, irrespective of PegIFN/RBV treatment duration.

30 or no clinical resistance, and the shortest treatment duration.

31 NA at RGT timepoints benefited from extended treatment duration.

32 eductions in CRP and SAA, continued over the treatment duration.

33 (cancer) to prevent late relapse and shorten treatment duration.

34 uprenorphine discontinuation irrespective of treatment duration.

35 niencies, and cost associated with a shorter treatment duration.

36 ias associated with non-random assignment of treatment duration.

37 s of high-risk patients over <3 years median treatment duration.

38 depressants but with a distinct, abbreviated treatment duration.

39 or benefit and risks of harm associated with treatment duration.

40 ality overall, irrespective of any increased treatment duration.

41 urther evaluate the effectiveness of shorter treatment durations.

42 er baseline infection prevalence and shorter treatment durations.

43 rapy and can identify candidates for shorter treatment durations.

44 pecially those that are intended for limited treatment durations.

45 al trials to compare outcomes after specific treatment durations.

46 usions of tissue plasminogen activator (mean treatment duration, 11 days).

47 Both groups had a similar treatment duration (15.9 vs. 15.4 d).

48 The study was terminated early (median treatment duration 157 days [range 6-203]) at the reques

49 s 15.9 weeks (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (ha

50 At EOP (mean treatment duration, 17 days), clinical success was 98.6%

51 weeks of peginterferon and ribavirin (total treatment duration, 28-48 wk).

52 stratified according to country and intended treatment duration (3, 6, or 12 months).

53 d in the intention-to-treat analyses (median treatment duration, 351 days).

54 , randomized, noninferiority clinical trial (treatment duration, 4 months; follow-ups, 6 months and 1

55 y was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR],

56 idual dosing regimens (240-1920 mg/d; median treatment duration, 90 days).

57 es for this entity, clinicians can determine treatment duration according to recommendations provided

58 study was to identify the minimum effective treatment duration across multiple genotypes.

59 Antimicrobial use, treatment duration, Acute Physiology and Chronic Health

60 ly affected by vasoconstrictor dose or type, treatment duration, age, baseline serum creatinine, bili

61 ration therapy was achieved through extended treatment duration and addition of ribavirin.

62 reas not covered by the performance measures-treatment duration and antimicrobial selection after add

63 ex CNS infections and may have relevance for treatment duration and assessment of persistent or recur

64 l recently, data on the relationship between treatment duration and associated cardiovascular risk we

65 esistant tumors correlating with bevacizumab treatment duration and causing three changes enabling re

66 as good indicators for the consideration of treatment duration and cessation for chronic hepatitis B

67 There was no interaction between treatment duration and chemotherapy regimen, ER/PgR, or

68 eems to improve survival through guidance of treatment duration and co-interventions.

69 y suggests a delicate balance exists between treatment duration and concentration in order to achieve

70 fear of side effects and concerns regarding treatment duration and cost.

71 -acting antivirals, which also offer reduced treatment duration and decreased toxicities, mean that p

72 We use this model to predict the effects of treatment duration and different doses of ALV plus RBV o

73 tently infected cells could therefore reduce treatment duration and facilitate immune reconstitution.

74 ons, and interferon-free regimens with short treatment duration and fewer side effects are the future

75 f clinical failure for CRP-guided antibiotic treatment duration and fixed 7-day treatment were noninf

76 virus (HCV) have evolved to provide shorter treatment duration and higher rates of sustained virolog

77 ion of the regimen could potentially prolong treatment duration and improve patients' outcomes, altho

78 enotype 1 HCV in HIV-infected men halved the treatment duration and increased the SVR rate.

79 itical to improving TB-therapy is shortening treatment duration and increasing therapeutic efficacy.

80 interferon-based treatment, but with shorter treatment duration and more favourable safety outcomes.

81 nt prescription (prescribed during OAT) with treatment duration and mortality.

82 Depending on the treatment duration and onset time relative to the stage

83 The current status quo of the lengthy treatment duration and poor treatment outcomes associate

84 The lengthy tuberculosis treatment duration and poor treatment outcomes associate

85 e treated with rituximab had shorter overall treatment duration and reduced 1-yr relapses than histor

86 There was no significant association between treatment duration and relapse risk.

87 Two patients reached the maximum 2-year treatment duration and remain in remission.

88 The association of treatment duration and survival was unstable when analyz

89 tion, and to assess the relationship between treatment duration and survival.

90 valid assessment of the association between treatment duration and survival.

91 cardiovascular magnetic resonance to inform treatment duration and the need to compare steroid-spari

92 tive at curing chronic infections, judged by treatment duration and therapeutic dose.

93 e size appears to be the driver of anti-VEGF treatment duration and therefore, dosing interval needs

94 ical trials are needed to establish the best treatment duration and to further assess the contributio

95 e; P = .0053) were experienced regardless of treatment duration and were similar to those for HCV-mon

96 ysician variability in prescribed antibiotic treatment durations and determine physician predictors o

97 ens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained vir

98 Long treatment durations and severe side effects have limited

99 pond to ICS therapy, and carefully selecting treatment durations and washout periods to assess increm

100 Clinical data were collected on natalizumab treatment, duration and management of the washout period

101 For each DAA, molecular structures, doses, treatment duration, and components of retrosynthesis wer

102 patients with high-risk disease, indefinite treatment duration, and decreased compliance over time a

103 es are needed to improve cure rates, shorten treatment duration, and improve tolerability.

104 entation, microbial documentation, location, treatment duration, and related persistent esthetic dama

105 o assess pathogen/patient factors related to treatment duration, and to assess the relationship betwe

106 ficant correlation was observed between age, treatment duration, and total dose and the development o

107 (MRD) status, durability of response, fixed treatment durations, and importantly, criteria for selec

108 in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to

109 With increasing age and treatment duration, antiepileptic drug withdrawal may be

110 and detailed information on drug dosage and treatment duration are needed.

111 cs to augment current approaches and shorten treatment duration are of critical importance for combat

112 -containing trials of mericitabine of longer treatment duration are ongoing.

113 codynamic models more predictive of curative treatment durations are set forth.

114 ients were subdivided by the 12- and 24-week treatment duration arms, HCV genotype, fibrosis stage, a

115 eceive a different and potentially incorrect treatment duration based solely on HCV RNA test method u

116 each patient's shortest effective (expected) treatment duration (based on time to clinical stability,

117 pes were tested using linear regression with treatment duration, baseline body weight, and medication

118 e, baseline visual acuity (VA), lesion size, treatment duration before tearing, and duration of follo

119 e was a positive association between ACD and treatment duration (beta = 0.14, P = .049), number of IV

120 artan (150 mg daily) and placebo with target treatment duration between 18 and 24 months.

121 Fisher exact tests compared planned adjuvant treatment duration between groups.

122 Superior outcomes became significant with treatment duration beyond 15 months, although rates of t

123 eatment for >10 years; patients with similar treatment duration but initiation of suppressive therapy

124 ghting bleeding risk before the selection of treatment duration, but no standardised tool exists for

125 GI and TE events) and resulted in decreased treatment duration compared with mFOLFIRINOX alone.

126 Conversely, antipsychotic treatment duration correlated significantly with higher

127 that the study type, adjustment for age/sex, treatment duration, cumulative dose, agents used in a co

128 Treatment with sorafenib resulted in a treatment duration-dependent significantly decreased upt

129 o to an individualized CRP-guided antibiotic treatment duration (discontinuation once CRP declined by

130 coustic pressure, microbubble concentration, treatment duration, DNA dosage, and number of treatments

131 neumonia, or did not have a total antibiotic treatment duration documented at discharge were more lik

132 tors, including the heterogeneity of asthma, treatment duration, dose, and differing outcome measures

133 reviews current attempts at shortening this treatment duration, emphasizing the likelihood of inconc

134 or patients who are still viremic at week 4, treatment durations even longer than 24 weeks are advise

135 ry outcome was the rate of excess antibiotic treatment duration (excess days per 30-day period).

136 structure infection (ABSSSI) do not address treatment duration for infections associated with bacter

137 Treatment duration for invasive mold disease (IMD) in pa

138 xed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3

139 nd tested the optimal combination, dose, and treatment duration for the prevention of T1D in NOD mice

140 c barrier to resistance, and provide shorter treatment durations for diverse patient populations.

141 rience has shown improved response rates and treatment durations for many patients with genotype 1 HC

142 of the use of ribavirin or extension of the treatment duration from 12 to 18 weeks; SVR12 rates rang

143 imen during the 1970s enabled a reduction in treatment duration from 12 to 6 months.

144 n, and cyclophosphamide, which shortened the treatment duration from 49 to 29 days.

145 t still substantial impact: shortening RS TB treatment duration from 6 to 2 mo lowered TB mortality b

146 Median treatment duration, from the beginning of the previous t

147 and using controller therapy for an extended treatment duration greater than 12 weeks.

148 seline at 96 weeks post-therapy for the long-treatment duration group (P = 0.03) and lower than basel

149 s of refrigerant gas; equipment failure; and treatment duration >10 min), a battery-operated thermal

150 Nonresponse at day 3 was a predictor of treatment duration >14 days, but not of clinical failure

151 ve incidence of optic neuropathy with longer treatment duration (>41 vs. </=41 days; HR, 3.46; 95% CI

152 nd release mechanisms, biocompatibility, and treatment duration have become highly sophisticated, the

153 tolerance increases resilience to antibiotic treatment duration in a nonspecific way, for example whe

154 etrospective assessment of DAPT score-guided treatment duration in a randomized clinical trial.

155 approach using (18)F-FDG PET/CT to determine treatment duration in high-risk SAB seems feasible and a

156 In addition, because treatment duration in most included trials was 4-12 week

157 However, because treatment duration in most trials was 4-12 weeks, the lo

158 ontrolled trials aiming to establish optimal treatment duration in patients at high risk of recurrent

159 possibly caused by higher doses and extended treatment duration in the individualized group.

160 ysis of all randomised, controlled trials of treatment duration in various cardiovascular disorders.

161 ination as a single formulation in different treatment durations in a broader population.

162 a weighing safety versus adequacy of shorter treatment durations in sepsis would be beneficial.

163 , as well as low adherence and wide range of treatment durations in the CRP-guided group.

164 t clinical trials of regimens with different treatment durations in treatment-naive and treatment-exp

165 antially higher response rates, with shorter treatment durations, in the majority of genotype 1 infec

166 tio of 1.1 (P = .04), indicating that longer treatment duration increased chance of complete recovery

167 The standard treatment duration is 12 months but shorter treatment co

168 Eligibility for shortened treatment duration is based on achieving undetectable HC

169 hat most responses are, however, partial and treatment duration is indefinite have stimulated interes

170 the tumour-bearing quadrant, which shortens treatment duration, is equally effective.

171 Further studies are needed to assess longer treatment duration, larger samples, and direct compariso

172 ment in EF for crossover trials, trials with treatment duration </=12 wk in length, studies published

173 e observed over a broad range of clopidogrel treatment durations (<6 months, 6 months to 1 year, 1 to

174 ers treatment initiation, regimen design and treatment duration, management of comorbid conditions, t

175 Combination therapy or longer treatment duration may be needed in immunocompromised pa

176 or more than 20 months, whereas much shorter treatment durations may be possible to achieve cure for

177 08 patients included, 123 received a shorter treatment duration (median 8 days) and 285 received a lo

178 Shortening of treatment duration might be achievable using an increase

179 ithout cirrhosis are limited; shortening the treatment duration might reduce the burden associated wi

180 In many cases, treatment duration must be individualised and might even

181 reatment duration (n = 169), or fixed 14-day treatment duration (n = 165).

182 ined by 75% from peak; n = 170), fixed 7-day treatment duration (n = 169), or fixed 14-day treatment

183 to prasugrel or ticagrelor with an intended treatment duration of 12 months.

184 9 were simultaneously initiated with a total treatment duration of 12 weeks.

185 e ibuprofen group (2045+/-246 mg) for a mean treatment duration of 20.3+/-16.0 months and a mean foll

186 TG dose of 20 mg (range: 20-40 mg), a median treatment duration of 23 months (IQR 10-47) and a median

187 (375 mg/m(2)) on cycles 2 and 5, for a total treatment duration of 23 weeks.

188 llow-up was until July 31, 2015, with a mean treatment duration of 3.4 years (SD 0.4, range 2.5-4.2).

189 atment) in 3 doses 14 days apart for a total treatment duration of 4 weeks, resulting in a total dose

190 h primary open-angle glaucoma with a minimum treatment duration of 4 weeks.

191 kin pigmentation appeared after a median HCQ treatment duration of 6.1 years (range, 3 months-22 year

192 dded to standard antipsychotic therapy for a treatment duration of 8 weeks.

193 emained smear positive after a median MDR-TB treatment duration of 8.8 weeks.

194 mean dose intensity (DI) was 95% with median treatment duration of approximately 9 months.

195 o assess the efficacy, safety, and effective treatment duration of grazoprevir (an HCV NS3/4A proteas

196 of the comparative efficacy and appropriate treatment duration of injectables are recommended.

197 ed no glucocorticoid treatment or cumulative treatment duration of less than 1 month versus treatment

198 cipants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall s

199 assess the safety and efficacy of an 8-week treatment duration of once-daily oral ombitasvir 25 mg,

200 f treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these pati

201 without loss of efficacy, currently reaching treatment durations of 17 (case 1) to 44 months (case 3)

202 o 90 days after clopidogrel cessation in all treatment durations of clopidogrel investigated after SV

203 s of the patients, need and type of surgical treatment, duration of operation, perioperative bleeding

204 diagnosis, allocated treatment and received treatment, duration of treatment and cause of discontinu

205 h team was not involved in deciding hospital treatment, duration of treatment in the hospital, and ad

206 de of drug-related side effects; response to treatment; duration of follow-up, and status at last fol

207 esence of vasculitis, prior immunomodulatory treatments, duration of infliximab treatment, dose recei

208 TTD during the first 14 days of treatment, a treatment duration often used in early bactericidal acti

209 els estimated the impact of planned adjuvant treatment duration on RFS.

210 ab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v

211 d affects bone mineralization, thus limiting treatment duration or demanding estrogen add-back approa

212 py did not differ significantly according to treatment duration or dosage among ribavirin-containing

213 Reducing treatment duration or improving ease of adherence had sm

214 timalarial therapy is enhanced by increasing treatment duration or maintaining higher blood drug conc

215 Longer treatment duration or the use of different regimen may s

216 they could be largely overcome by extending treatment duration or through treatment intensification.

217 mycin, no difference in final visual acuity, treatment duration, or need for surgery was found.

218 O scores declined (up to -5.5% regardless of treatment duration; P < 0.0001).

219 y adverse events (15%) did not increase with treatment duration past 1 year.

220 r infectious diseases, with implications for treatment duration, patient compliance, and more optimal

221 th delayed treatment initiation and extended treatment duration, persistent viral DNA has been shown

222 ary annual out-of-pocket costs for a typical treatment duration ranged from $6,456 (interquartile ran

223 The treatment duration ranged from 6 weeks to 3 years.

224 probiotics and 12 evaluated synbiotics, with treatment duration ranging from 8 to 28 wk.

225 Significant harm is possible with treatment durations ranging from 5-24 hours, which may r

226 y drug, and safety analyses were done by the treatment duration received (12 weeks or 16 weeks).

227 6 months of continuous treatment, a minimum treatment duration recently endorsed by the National Qua

228 average individual, we test whether pooling treatment durations recommended by different prescribers

229 these effects will be sustained with longer treatment durations remains to be determined.

230 d could be applied to estimating the minimum treatment duration required for HCV infection.

231 blished data are conflicting regarding dose, treatment duration, requirement for combinatorial agents

232 ers to improvements in outcomes include long treatment duration (resulting in poor patient adherence

233 asis need to be established, although longer treatment duration seems to confer better results.

234 Eligibility for shortened treatment duration should be based on achieving undetect

235 The analyses of treatment duration showed that 1 year after the initiati

236 hout ribavirin and for both 12 and 18 weeks' treatment duration, showed high rates of efficacy in pre

237 ogen characteristics are not associated with treatment duration; survivor bias precludes a valid asse

238 itive cancers, an individualized approach to treatment duration that is based on considerations of ri

239 h different mechanisms may allow for shorter treatment durations that are effective across multiple g

240 e easily controlled by changing the AC field treatment duration, thus opening the pathway to combined

241 ed treatment could allow a reduction in mean treatment duration to 25.3 weeks and attain a 78.6% SVR

242 Administration of HR(80)Z allowed 9-week treatment duration to be effective without relapse of in

243 direct-acting antiviral regimens will allow treatment duration to be shortened in recent, predominan

244 liver high rifapentine exposures can shorten treatment duration to less than 6 months.

245 However, shortening the treatment duration to less than 8 weeks could potentiall

246 e eligible for response-guided shortening of treatment duration to W28 and all of these patients had

247 ing bias in recommendations about antibiotic treatment durations to quantify current levels of overpr

248 criteria required for registration, shorten treatment duration, treat drug-resistant infection, and

249 t variable as random factor and variables of treatment duration, type, and interaction as predictors

250 However, despite very short treatment duration UHPH may lead to changes in chemical

251 ral antibiotic switch after >/=5 days (total treatment duration up to 10 days or 14 days for patients

252 clude a relatively small number of patients, treatment duration up to only 56 days, lack of quantitat

253 ients and study investigators were masked to treatment duration up to week 12 but not to treatment al

254 The mean treatment duration was 11 weeks (range, 4-16 weeks), and

255 hs (range, 4.3 to 57 months), whereas median treatment duration was 13.9 months (for 855 patient-mont

256 Median treatment duration was 15.1 months (range, 0.3-32.2 mont

257 Treatment duration was 16 weeks.

258 Median treatment duration was 16.6 months (IQR 10.1-21.1) in th

259 Mean treatment duration was 19.4 years (SD 2.2) with an avera

260 Median treatment duration was 2.6 years (IQR 2.0-3.4; 136 weeks

261 Median treatment duration was 22 weeks in both arms.

262 The median treatment duration was 22.5 weeks.

263 Total treatment duration was 24 weeks or 48 weeks (simeprevir

264 Treatment duration was 24 weeks or 48 weeks in the simep

265 The median treatment duration was 3.5 months.

266 Median treatment duration was 5.3 months (IQR 2.8-7.3) in the n

267 .5 [SD, 7.1] years; 49.2% women), the median treatment duration was 5.3 years and 90.5% completed the

268 Median treatment duration was 5.3 years.

269 Mean treatment duration was 5.8 months, and median duration o

270 rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6),

271 Median treatment duration was 6 weeks (IQR 6-8).

272 Median treatment duration was 7 months (range, 1 to >/= 29 mont

273 ctively, was allowed after 3 days; the total treatment duration was 7 to 14 days.

274 2 hours) was allowed after 3 days; the total treatment duration was 7 to 14 days.

275 The median treatment duration was 8.3 months; 46% of patients were

276 Median treatment duration was 9.6 months; 19 patients (42%) rem

277 In cases with available data, median treatment duration was 9.8 months (IQR 3.6-17.4; n=96) a

278 In the current study, we found that treatment duration was associated with a reduction in HI

279 Treatment duration was event-driven, and interim analyse

280 Unique to other studies, the treatment duration was guided by the presence of baselin

281 Median treatment duration was longer in the KdD versus the Kd g

282 Treatment duration was scheduled for 1 year and stopped

283 Treatment duration was shortened in 11 of the 29 patient

284 In treated neonates, NAS treatment duration was shorter (-8.46 days, 95% CI: -14.

285 Treatment duration was variable, ending 48 weeks after t

286 ; 95% CI, 0.76-0.95; P<0.01) 12 months after treatment; duration was not significantly associated wit

287 originator and biosimilar drugs, the median treatment duration was38 months (range: 8-131 months) an

288 After considering treatment duration, we found that almost half of the pat

289 The median overall survival and treatment duration were 85.8 and 40.1 months, respective

290 Treatment effects after covarying for treatment duration were also found for PCS and several s

291 , clinical setting, levosimendan dosage, and treatment duration were extracted.

292 n serum, previous immunosuppressant use, and treatment duration, which were estimated using populatio

293 Treatment duration with 10 mg lorcaserin twice daily or

294 f the patients would be eligible for shorter treatment duration with Abbott RealTime versus 72% with

295 Despite longer treatment duration with alectinib than crizotinib (14.7

296 Median treatment duration with lacosamide/placebo was 143/65 da

297 similar in each group despite longer median treatment duration with siltuximab than with placebo (37

298 aratide should be considered; however, since treatment duration with these drugs is restricted to 18-

299 ncrease mortality risk but may also increase treatment duration, with overall benefit.

300 des were characterized by a relatively short treatment duration, yet the women had a notably high rat